Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7790121 in moderate to severe rheumatoid arthritis after inadequate response or intolerance to TNF and/or JAK inhibitors
2025-521034-28-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing RO7790121 with Placebo (2 arms). Primary endpoint: Change from baseline in DAS28-CRP at Week 14. Planned start Dec 2025; status: authorised.
02
Drugs
afimkibart
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2025-521034-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521034-28-00.